CLAIMS

I claim:

the first atts time that then seed the most to that it that it tout when

1	1. An immunodeficient mouse comprising:
2	a) human T lymphocytes expressing the CD45 antigen, wherein at least 5% of the
3	human T cells expressing the CD45 antigen represent immature naive T lymphocytes; and
4	b) human tumor cells;
5	wherein said immunodeficient mouse is a SCID/beige mouse.
1 2	2. The mouse according to claim 1, wherein said tumor cells are from a tumor cell line.
1	3. The mouse according to claim 1, wherein said tumor cells are from a primary tumor.
1 2	4. The mouse according to claim 1, wherein said tumor cells are derived from central nervous system cells.
1 2	5. The mouse according to claim 4, wherein said tumor cells derived from central nervous system cells are glioblastoma cells.
1 2	6. The mouse according to claim 1, wherein at least one of said tumor cells contains at least one transgene.
1 2	7. The mouse according to claim 6, wherein at least one of said transgenes is a human immunomodulator gene.

8

1	8. The mouse according to claim 6, wherein at least one of said transgenes is delivered
2	by a viral vector.
1	9. The mouse according to claim 1, further comprising an immunogen.
1	10. The mouse according to claim 9, wherein said immunogen is a vaccine.
1 2	11. A tumor cell vaccine comprising a tumor cell expressing B7-2 and at least one additional immune modulator.
1 2	12. The vaccine according to claim 11, wherein said at least one additional immune modulator is a cytokine.
1 2 3 4	13. The vaccine according to claim 12, wherein said cytokine is selected from the group consisting of interleukin 2, interleukin 4, interleukin 6, interleukin 7, interleukin 12, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interferon-gamma, tumor necrosis factor-alpha.
1	14. A method of treating a tumor comprising:
2	a) providing:
3	 a subject having a tumor of the central nervous system;
4	ii) an expression vector encoding the human B7-2 protein and at
5	least one additional immune modulator;
6	b) transferring said expression vector into said tumor under conditions
7	such that said B7-2 protein and said immune-modulator are expressed by at least a

portion of said tumor.

- 15. The method according to claim 14 further comprising, prior to transfer of said expression vector, the step of removing at least a portion of said tumor from said subject and following said transfer of said expression vector, irradiating said tumor cells expressing said B7-2 protein and said immune-modulator and introducing said irradiated tumor cells back into said subject to create an immunized subject.
- 16. The method according to claim 15 further comprising, introducing at least one additional dose of irradiated tumor cells expressing said B7-2 protein and said immune-modulator into said immunized subject.